French pharmaceutical giant Sanofi (NASDAQ: SNY) has expanded its partnership with UK-based AI-driven precision drug design company Exscientia (NASDAQ: EXAI) by in-licensing a program in an undisclosed therapeutic area. This move builds on a 2022 agreement aimed at developing up to 15 novel small-molecule candidates across oncology and immunology. The newly licensed program is highlighted by a series of potential best-in-class leads that have demonstrated promising potency and selectivity in vitro.
Financial terms of the agreement entail Exscientia receiving up to USD 345 million in upfront and milestone payments, complemented by potential sales royalties. This collaboration follows a similar agreement Exscientia entered into earlier this year with German major Merck (ETR: MRK).- Fineline.com
